What are the ARBITER 6-HALTS study findings regarding the clinical efficacy of ezetimibe?
Ezetimibe is a drug that inhibits intestinal absorption of cholesterol; it is marketed alone (Zetia) and in combination with simvastatin (Vytorin). Despite the fact that ezetimibe is known to lower low-density lipoprotein cholesterol (LDL) levels in combination with an HMG-coenzyme A reductase inhibitor (statin), clinical efficacy is still in question. Studies that have investigated ezetimibe’s effects on cardiovascular events have not demonstrated a clear, definitive benefit. For example, in the SEAS trial, long-term therapy with ezetimibe/simvastatin in patients with mild-to-moderate asymptomatic aortic stenosis (AS) had no overall effect on the AS but reduced the risk of ischemic cardiovascular events, especially the need for coronary artery bypass grafting (CABG) [see FAQ on SEAS trial, October 2008].1 A recent study published in the New England Journal of Medicine continues the controversy of the role of ezetimibe in the treatment of dyslipidemia. The ARBITER 6-HALTS Trial ARBITER
Related Questions
- You have mentioned a clinical study in the original Question and Answer page on HairlossSucks back in March. When do you plan to release the result of this study?
- What motivated Dr. McConochie to study political psychology after years as a clinical and I/O psychologist?
- Why study Masters in Clinical Psychology at UNSW?
